Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis

被引：0
|
作者：
Michael Pfeifer
Raymond R. Townsend
Michael J. Davies
Ujjwala Vijapurkar
Jimmy Ren
机构：
[1] Janssen Scientific Affairs,Perelman School of Medicine
[2] LLC,undefined
[3] University of Pennsylvania,undefined
[4] Janssen Research & Development,undefined
[5] LLC,undefined
来源：
Cardiovascular Diabetology | / 16卷
关键词：
Canagliflozin; Sodium glucose co-transporter 2 (SGLT2) inhibitor; Type 2 diabetes; Blood pressure; Ambulatory blood pressure monitoring; Pulse pressure; Mean arterial pressure; Double product;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials
    Richard E. Gilbert
    Christian Mende
    Ujjwala Vijapurkar
    Sue Sha
    Michael J. Davies
    Mehul Desai
    Diabetes Therapy, 2017, 8 : 451 - 458
  • [32] Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials
    Gilbert, Richard E.
    Mende, Christian
    Vijapurkar, Ujjwala
    Sha, Sue
    Davies, Michael J.
    Desai, Mehul
    DIABETES THERAPY, 2017, 8 (02) : 451 - 458
  • [33] Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus
    Molugulu, Nagashekhara
    Yee, Lai Shu
    Ye, Yew Tze
    Khee, Tan Chew
    Nie, Lee Zhen
    Yee, Neoh Jia
    Yee, Tian Kar
    Liang, Tan Chee
    Kesharwani, Prashant
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 132 : 157 - 168
  • [34] How attractive is the combination of a sodium glucose co-transporter 2 inhibitor with a dipeptidyl peptidase 4 inhibitor in the treatment of type 2 diabetes?
    Schernthaner, G.
    Schernthaner-Reiter, M. H.
    DIABETES OBESITY & METABOLISM, 2015, 17 (07): : 613 - 615
  • [35] The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes
    Whalen, Karen
    Miller, Shannon
    St Onge, Erin
    CLINICAL THERAPEUTICS, 2015, 37 (06) : 1150 - 1166
  • [36] Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
    Filippatos, T. D.
    Tsimihodimos, V.
    Elisaf, M. S.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (12) : 1581 - 1583
  • [37] Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension
    Amin, N. B.
    Wang, X.
    Mitchell, J. R.
    Lee, D. S.
    Nucci, G.
    Rusnak, J. M.
    DIABETES OBESITY & METABOLISM, 2015, 17 (08): : 805 - 808
  • [38] Invokana (Canagliflozin) as a Dual Inhibitor of Acetylcholinesterase and Sodium Glucose Co-Transporter 2: Advancement in Alzheimer's Disease-Diabetes Type 2 Linkage via an Enzoinformatics Study
    Rizvi, Syed M. D.
    Shakil, Shahnawaz
    Biswas, Deboshree
    Shakil, Shazi
    Shaikh, Sibhghatulla
    Bagga, Paramdeep
    Kamal, Mohammad A.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2014, 13 (03) : 447 - 451
  • [39] Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK
    Evans, Marc
    Achha, Sayeed
    Neslusan, Cheryl
    DIABETES THERAPY, 2017, 8 (05) : 1175 - 1185
  • [40] Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK
    Marc Evans
    Sayeed Achha
    Cheryl Neslusan
    Diabetes Therapy, 2017, 8 : 1175 - 1185
12345